Large portfolio Abdi İbrahim operates with the largest product portfolio in Turkey, including nearly 250 brands and over 500 products, developed in-house and in partnership with licensors. This breadth suggests cross-selling opportunities across multiple therapeutic areas and the potential to introduce new formulations or line extensions to existing customers.

Global footprint The company exports to more than 70 countries and operates R&D centers and production facilities outside Turkey, indicating appeal to multinational distributors and opportunity to expand supply agreements, contract manufacturing, or strategic partnerships in international markets.

Scale and growth With significant revenue and a large workforce, plus ongoing investments in new facilities and technology, there is potential for up-selling high-value manufacturing, sterile injectables, oncology products, and biotech services to existing clients and regional partners.

Sustainability edge A commitment to Global Reporting Initiative level A sustainability practices and UN Global Principles Agreement strengthens credibility with buyers prioritizing ESG, opening doors to sustainability-aligned procurement programs and long-term contracting with government and health systems.

Innovation engine As the first accredited R&D center in the industry and the largest biotechnological manufacturing facility in Türkiye (AbdiBio), there is a strong opportunity to position as a supplier of advanced R&D services, contract research, and innovative biologics or biotech manufacturing collaborations.